Cargando…

Novel and Investigational Treatments for Onychomycosis

Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregoriou, Stamatios, Kyriazopoulou, Maria, Tsiogka, Aikaterini, Rigopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604567/
https://www.ncbi.nlm.nih.gov/pubmed/36294644
http://dx.doi.org/10.3390/jof8101079
_version_ 1784817846459564032
author Gregoriou, Stamatios
Kyriazopoulou, Maria
Tsiogka, Aikaterini
Rigopoulos, Dimitrios
author_facet Gregoriou, Stamatios
Kyriazopoulou, Maria
Tsiogka, Aikaterini
Rigopoulos, Dimitrios
author_sort Gregoriou, Stamatios
collection PubMed
description Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe emotional stress. Treatment failure and relapse of the infection are the most frequent problems, though new issues have become the new challenges in the therapeutic approach to onychomycosis. Resistance to antifungals, an increasing number of comorbidities, and polydrug use among the ageing population are imperatives that impose a shift to safer drugs. Topical antifungals are considered less toxic and minimally interact with other drugs. The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients’ health. Efinaconazole, Tavaborole, and Luliconazole have been added to physicians’ weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers.
format Online
Article
Text
id pubmed-9604567
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96045672022-10-27 Novel and Investigational Treatments for Onychomycosis Gregoriou, Stamatios Kyriazopoulou, Maria Tsiogka, Aikaterini Rigopoulos, Dimitrios J Fungi (Basel) Review Onychomycosis is a common nail disease caused by fungi. The primary pathogens are dermatophytes; however, yeasts, non-dermatophyte moulds, and mixed fungal populations may also contribute to the development of a recalcitrant condition, usually accompanied by difficulties in everyday life and severe emotional stress. Treatment failure and relapse of the infection are the most frequent problems, though new issues have become the new challenges in the therapeutic approach to onychomycosis. Resistance to antifungals, an increasing number of comorbidities, and polydrug use among the ageing population are imperatives that impose a shift to safer drugs. Topical antifungals are considered less toxic and minimally interact with other drugs. The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients’ health. Efinaconazole, Tavaborole, and Luliconazole have been added to physicians’ weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers. MDPI 2022-10-14 /pmc/articles/PMC9604567/ /pubmed/36294644 http://dx.doi.org/10.3390/jof8101079 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gregoriou, Stamatios
Kyriazopoulou, Maria
Tsiogka, Aikaterini
Rigopoulos, Dimitrios
Novel and Investigational Treatments for Onychomycosis
title Novel and Investigational Treatments for Onychomycosis
title_full Novel and Investigational Treatments for Onychomycosis
title_fullStr Novel and Investigational Treatments for Onychomycosis
title_full_unstemmed Novel and Investigational Treatments for Onychomycosis
title_short Novel and Investigational Treatments for Onychomycosis
title_sort novel and investigational treatments for onychomycosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604567/
https://www.ncbi.nlm.nih.gov/pubmed/36294644
http://dx.doi.org/10.3390/jof8101079
work_keys_str_mv AT gregorioustamatios novelandinvestigationaltreatmentsforonychomycosis
AT kyriazopouloumaria novelandinvestigationaltreatmentsforonychomycosis
AT tsiogkaaikaterini novelandinvestigationaltreatmentsforonychomycosis
AT rigopoulosdimitrios novelandinvestigationaltreatmentsforonychomycosis